[{"orgOrder":0,"company":"Sonoma Pharmaceuticals","sponsor":"Brill International S.L","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Hypochlorous Acid","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Sonoma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Sonoma Pharmaceuticals \/ Brill International S.L","highestDevelopmentStatusID":"12","companyTruncated":"Sonoma Pharmaceuticals \/ Brill International S.L"},{"orgOrder":0,"company":"Sonoma Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Hypochlorous Acid","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sonoma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Sonoma Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sonoma Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Sonoma Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Hypochlorous Acid","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sonoma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Sonoma Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sonoma Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Sonoma Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Hypochlorous Acid","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sonoma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Sonoma Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sonoma Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Sonoma Pharmaceuticals","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Hypochlorous Acid","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sonoma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sonoma Pharmaceuticals \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Sonoma Pharmaceuticals \/ Daewoong Pharmaceutical"}]

Find Clinical Drug Pipeline Developments & Deals by Sonoma Pharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : Under the terms of the agreement, Daewoong Pharmaceutical will have the exclusive right to market, sell and distribute Primocyn (hypochlorous acid) Skin Solution products, containing Sonoma's Microcyn technology, in South Korea.

                          Brand Name : Primocyn

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          January 31, 2023

                          Lead Product(s) : Hypochlorous Acid

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved

                          Sponsor : Daewoong Pharmaceutical

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          02

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : Regenacyn Plus (Hypochlorous acid), is an anti-allergic, anti-inflammatory and antipruritic most effective scar gel. It has dual action healing process for infection control, improving new and old keloid and hypertrophic scars and accelerating wound heal...

                          Brand Name : Regenacyn Plus

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          January 04, 2023

                          Lead Product(s) : Hypochlorous Acid

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : Reliefacyn (hypochlorous acid) is antipruritic, anti-inflammatory, and anti-allergic. Reliefacyn alleviates symptoms such as red bumps, itchy, painful and scaly rashes, shallow skin fissures and peeling, and effectively manages symptoms of eczema/atopic ...

                          Brand Name : Reliefacyn

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 27, 2022

                          Lead Product(s) : Hypochlorous Acid

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : Regenacyn Advanced Scar Gel protects and moisturizes wound and scar sites to promote lighter, flatter and less prominent scarring. Regenacyn Advanced Scar Gel is non-toxic, non-irritating and non-sensitizing.

                          Brand Name : Regenacyn

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 28, 2021

                          Lead Product(s) : Hypochlorous Acid

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : Sonoma has agreed on a 10-year license, distribution and supply agreement with its distribution partner Brill International S.L. to market the eye care product under the private label Ocudox™ in the European markets of Italy, Germany, Spain, Portugal a...

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          May 26, 2020

                          Lead Product(s) : Hypochlorous Acid

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved

                          Sponsor : Brill International S.L

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank